Jefferies Financial Group Inc. Invests $1.10 Million in Glaukos Corporation $GKOS

Jefferies Financial Group Inc. bought a new position in shares of Glaukos Corporation (NYSE:GKOS) in the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The firm bought 7,856 shares of the medical instruments supplier’s stock, valued at approximately $1,098,000.

Several other hedge funds have also recently bought and sold shares of GKOS. AQR Capital Management LLC lifted its holdings in shares of Glaukos by 2.6% during the first quarter. AQR Capital Management LLC now owns 7,788 shares of the medical instruments supplier’s stock valued at $766,000 after acquiring an additional 198 shares during the period. Jones Financial Companies Lllp grew its holdings in shares of Glaukos by 1,405.9% in the 1st quarter. Jones Financial Companies Lllp now owns 2,560 shares of the medical instruments supplier’s stock worth $252,000 after purchasing an additional 2,390 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its holdings in shares of Glaukos by 41.7% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 229,994 shares of the medical instruments supplier’s stock worth $22,636,000 after purchasing an additional 67,668 shares during the last quarter. M&T Bank Corp acquired a new stake in shares of Glaukos during the 2nd quarter worth about $203,000. Finally, Gamco Investors INC. ET AL increased its position in shares of Glaukos by 10.7% during the 2nd quarter. Gamco Investors INC. ET AL now owns 8,001 shares of the medical instruments supplier’s stock worth $826,000 after purchasing an additional 773 shares in the last quarter. 99.04% of the stock is currently owned by institutional investors and hedge funds.

Glaukos Stock Performance

Shares of Glaukos stock opened at $179.95 on Monday. The firm has a fifty day moving average of $162.64 and a two-hundred day moving average of $134.10. The company has a debt-to-equity ratio of 0.10, a quick ratio of 4.46 and a current ratio of 5.04. The stock has a market capitalization of $10.61 billion, a price-to-earnings ratio of -55.37 and a beta of 0.78. Glaukos Corporation has a 52 week low of $73.16 and a 52 week high of $191.62.

Glaukos (NYSE:GKOS) last announced its quarterly earnings data on Wednesday, July 29th. The medical instruments supplier reported ($0.14) EPS for the quarter, topping analysts’ consensus estimates of ($0.21) by $0.07. The business had revenue of $185.61 million during the quarter, compared to analysts’ expectations of $150.93 million. Glaukos had a negative return on equity of 6.37% and a negative net margin of 30.68%.The firm’s quarterly revenue was up 49.6% compared to the same quarter last year. During the same period in the previous year, the firm earned ($0.24) earnings per share. As a group, equities research analysts predict that Glaukos Corporation will post -0.32 EPS for the current year.

Insider Buying and Selling

In related news, Director Leana Wen sold 525 shares of the stock in a transaction that occurred on Friday, July 31st. The shares were sold at an average price of $167.63, for a total value of $88,005.75. Following the sale, the director directly owned 21,092 shares in the company, valued at $3,535,651.96. This trade represents a 2.43% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, COO Joseph E. Gilliam sold 60,000 shares of Glaukos stock in a transaction that occurred on Tuesday, August 11th. The stock was sold at an average price of $179.74, for a total transaction of $10,784,400.00. Following the transaction, the chief operating officer directly owned 72,588 shares in the company, valued at $13,046,967.12. The trade was a 45.25% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 113,025 shares of company stock valued at $19,600,006 over the last 90 days. 5.90% of the stock is owned by corporate insiders.

Analyst Upgrades and Downgrades

GKOS has been the topic of several recent analyst reports. Weiss Ratings reissued a “sell (d-)” rating on shares of Glaukos in a report on Friday, July 17th. Stifel Nicolaus upped their price target on shares of Glaukos from $175.00 to $190.00 and gave the stock a “buy” rating in a research report on Thursday, July 30th. BTIG Research increased their price target on shares of Glaukos from $193.00 to $202.00 and gave the company a “buy” rating in a research note on Thursday, August 20th. Piper Sandler restated an “overweight” rating and issued a $195.00 price objective (up from $165.00) on shares of Glaukos in a research report on Thursday, July 30th. Finally, Wall Street Zen raised Glaukos from a “hold” rating to a “buy” rating in a report on Saturday, August 1st. Twelve investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, Glaukos currently has a consensus rating of “Moderate Buy” and a consensus target price of $178.08.

Glaukos Company Profile

Glaukos Corporation is a medical technology company specializing in the development, manufacturing and commercialization of innovative therapies for patients with glaucoma and other chronic eye diseases. The company’s core offerings focus on micro-invasive glaucoma surgery (MIGS), designed to reduce intraocular pressure and manage glaucoma more safely and effectively than traditional surgical approaches. Glaukos’s flagship products include the iStent, iStent inject and iStent infinite trabecular micro-bypass stents, which are implanted during cataract surgery to improve aqueous outflow and help control eye pressure.

Beyond its MIGS portfolio, Glaukos has expanded into sustained drug-delivery solutions.